FDA Reviewing Potential Anti-Arrhythmic Claims For Ranexa(R)
Dec 9th 2007Drug InformationCardiovascular
CV Therapeutics, Inc. (Nasdaq: CVTX) announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa(R) (ranolazine extended-release tablets) as part of its ongoing review of the Company’s supplemental new drug application (sNDA). [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
